PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23727576-0 2013 Activation of PPARalpha by Wy-14643 ameliorates systemic lipopolysaccharide-induced acute lung injury. pirinixic acid 27-35 peroxisome proliferator activated receptor alpha Mus musculus 14-23 23724059-10 2013 A single dose of the synthetic PPARalpha agonist WY14643 (WY, 80 mg/kg, i.p.) pirinixic acid 49-56 peroxisome proliferator activated receptor alpha Mus musculus 31-40 23685729-2 2013 In this study, we investigated the effects of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist WY14643 and insulin-like growth factor-1 (IGF-1) on the expression and activity of SULT1E1 in vascular cells. pirinixic acid 120-127 peroxisome proliferator activated receptor alpha Mus musculus 100-110 23727576-2 2013 The activation of peroxisome proliferator-activated receptor-alpha (PPARalpha) by its ligands, which include Wy-14643, has been implicated as a potential anti-inflammatory therapy. pirinixic acid 109-117 peroxisome proliferator activated receptor alpha Mus musculus 18-66 23727576-2 2013 The activation of peroxisome proliferator-activated receptor-alpha (PPARalpha) by its ligands, which include Wy-14643, has been implicated as a potential anti-inflammatory therapy. pirinixic acid 109-117 peroxisome proliferator activated receptor alpha Mus musculus 68-77 23362873-6 2013 The treatment of mice skin with the PPARgamma and PPARalpha agonists, pioglitazone and WY14643, was associated with significant increase in photons emission reaching maximal signalling at 6 h. We have performed dose response studies by testing a large range of pioglitazone and WY14643 concentrations on mouse skin. pirinixic acid 87-94 peroxisome proliferator activated receptor alpha Mus musculus 50-59 23388073-5 2013 PPARalpha agonist WY14643 was administered to mice during the last couple of weeks. pirinixic acid 18-25 peroxisome proliferator activated receptor alpha Mus musculus 0-9 23362873-6 2013 The treatment of mice skin with the PPARgamma and PPARalpha agonists, pioglitazone and WY14643, was associated with significant increase in photons emission reaching maximal signalling at 6 h. We have performed dose response studies by testing a large range of pioglitazone and WY14643 concentrations on mouse skin. pirinixic acid 278-285 peroxisome proliferator activated receptor alpha Mus musculus 50-59 23362873-7 2013 The specificity of bioluminescence signal induced by pioglitazone and WY14643 was assessed using PPARgamma and PPARalpha antagonists, GW9662 and GW6471, respectively. pirinixic acid 70-77 peroxisome proliferator activated receptor alpha Mus musculus 111-120 22607296-4 2012 In this study, we examined whether co-treatment with topical peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists (e.g. WY14643) reduce retinoid dermatitis in hairless mouse skin. pirinixic acid 137-144 peroxisome proliferator activated receptor alpha Mus musculus 111-120 22160327-5 2012 A PPAR activator (Wy14643) and DMSO (vehicle) was introduced into control and delta337T thyroid hormone receptor (TRbeta1) transgenic mice. pirinixic acid 18-25 peroxisome proliferator activated receptor alpha Mus musculus 2-6 22274564-9 2012 Large similarity was also observed between PPARalpha agonist Wy14643 and C22:6. pirinixic acid 61-68 peroxisome proliferator activated receptor alpha Mus musculus 43-52 19998413-9 2010 Mitochondriogenesis could be accelerated by PPAR-alpha specific agonist WY14643 and abolished by its antagonist GW6471 at the early stage. pirinixic acid 72-79 peroxisome proliferator activated receptor alpha Mus musculus 44-54 22208561-5 2011 Induction of PPARalpha by PPARalpha agonist WY14643 treatment for 2 weeks ameliorated the severity of liver injury and restored expression of genes altered by ethanol treatment. pirinixic acid 44-51 peroxisome proliferator activated receptor alpha Mus musculus 13-22 22208561-5 2011 Induction of PPARalpha by PPARalpha agonist WY14643 treatment for 2 weeks ameliorated the severity of liver injury and restored expression of genes altered by ethanol treatment. pirinixic acid 44-51 peroxisome proliferator activated receptor alpha Mus musculus 26-35 21633371-3 2011 Therefore, we examined whether sequential topical GCs followed by topical Wy14643 (a ligand of PPARalpha) might be more effective than either alone for atopic dermatitis (AD) in a hapten (oxazolone (Ox))-induced murine model with multiple features of AD (Ox-AD). pirinixic acid 74-81 peroxisome proliferator activated receptor alpha Mus musculus 95-104 21245137-6 2011 In line, Wy-14643-mediated PPARalpha activation in the wild-type mouse heart resulted in up-regulation of igf-1 transcript abundance and provided protection against cardiomyocyte apoptosis following ischemia/reperfusion or biomechanical stress. pirinixic acid 9-17 peroxisome proliferator activated receptor alpha Mus musculus 27-36 21963508-4 2011 In addition, the maximal efficacy of IMB-05 and IMB-15 in activating PPARalpha/gamma was approximately 30% of that observed with Wy14643 and rosiglitazone. pirinixic acid 129-136 peroxisome proliferator activated receptor alpha Mus musculus 69-84 21846997-6 2011 In contrast, wy-14643, which activates PPAR-alpha more selectively than clofibrate, had no effect. pirinixic acid 13-21 peroxisome proliferator activated receptor alpha Mus musculus 39-49 21811494-3 2011 We suggested that the regulatory mechanism of PPARalpha activation by WY14643 in mouse small intestine is more complicated than in liver due to more involved pathways. pirinixic acid 70-77 peroxisome proliferator activated receptor alpha Mus musculus 46-55 20650341-4 2010 Mice with DSS-induced colitis were injected with Wy-14643 (2 mg/kg) as a PPARalpha agonist every day from day 0 to day 5. pirinixic acid 49-57 peroxisome proliferator activated receptor alpha Mus musculus 73-82 20558911-3 2010 WY14643, a potent PPARalpha agonist, was administered intraperitoneally either simultaneously (WY14643-late group) or 3 days before viral inoculation (WY14643-early group). pirinixic acid 0-7 peroxisome proliferator activated receptor alpha Mus musculus 18-27 20452409-4 2010 Prior work has shown urea cycle gene expression to be reduced in mice by another PPARalpha ligand, WY14643. pirinixic acid 99-106 peroxisome proliferator activated receptor alpha Mus musculus 81-90 19698765-6 2009 In accordance, systemic WY14643 was able to block sensitization to morphine, confirming that PPAR-alpha plays a homeostatic role opposing morphine-induced motor sensitization, likely through a reduction of inflammation-associated changes. pirinixic acid 24-31 peroxisome proliferator activated receptor alpha Mus musculus 93-103 19805517-4 2009 Remarkably, several genes induced by Wy14643 were upregulated by fasting independently of PPARalpha, including Lpin2 and St3gal5, suggesting involvement of another transcription factor. pirinixic acid 37-44 peroxisome proliferator activated receptor alpha Mus musculus 90-99 19531609-10 2009 Selective PPARA agonism with WY14643 also induced SLC16A7 and catalase expression in the presence of glucose. pirinixic acid 29-36 peroxisome proliferator activated receptor alpha Mus musculus 10-15 19593819-7 2009 Treatment with another PPARalpha agonist, WY14643, showed contrasting effects on these marker gene expressions in wild-type and SHP null mice, demonstrating the specificity of fenofibrate in activating AMPK signaling. pirinixic acid 42-49 peroxisome proliferator activated receptor alpha Mus musculus 23-32 19531609-6 2009 Zygotes were cultured with or without glucose and with the PPARA-selective agonist WY14643 and the developing embryos assessed for expression of PPARA and phospho-PPARA in relation to the upregulation of SLC16A7 and catalase driven by glucose deprivation, indicative of peroxisomal proliferation. pirinixic acid 83-90 peroxisome proliferator activated receptor alpha Mus musculus 59-64 18520060-4 2008 Further, the PPARalpha ligand Wy14643 increased the expression of Octn2 in wild-type mice, but not in PPARalpha knockout mice. pirinixic acid 30-37 peroxisome proliferator activated receptor alpha Mus musculus 13-22 19438714-8 2009 A known PPAR activator (Wy14643) and dimethylsulfoxide (vehicle) were introduced into control (FVB) and delta337T thyroid hormone receptor (TRbeta) transgenic mice. pirinixic acid 24-31 peroxisome proliferator activated receptor alpha Mus musculus 8-12 19165156-7 2009 Characterizing the in vitro functional properties of this mutant, we show that PPARgammamut preferentially responds to the PPARalpha agonist, WY-14643, over the TZD, pioglitazone. pirinixic acid 142-150 peroxisome proliferator activated receptor alpha Mus musculus 123-132 19136022-7 2009 Next, we determined commonalities and differences in the temporal response to phenobarbital and WY-14,643, a prototypical activator of PPAR alpha. pirinixic acid 96-105 peroxisome proliferator activated receptor alpha Mus musculus 135-145 19017711-5 2009 The hypolipidemic fibrate PPAR alpha agonist WY-14 643 decreased the glucose-induced calcium oscillations in intact islets. pirinixic acid 45-54 peroxisome proliferator activated receptor alpha Mus musculus 26-36 17951219-4 2008 Treatment with PPARalpha agonists (WY14643, GW7647, and ciprofibrate) significantly increased cardiomyogenesis and expression of the cardiac genes MLC2a, ANP, MHC-beta, MLC2v, and cardiac alpha-actin. pirinixic acid 35-42 peroxisome proliferator activated receptor alpha Mus musculus 15-24 18205750-6 2008 Both NAC and WY14643, a peroxisome proliferator-activated receptor (PPAR)-alpha agonist attenuated these LCM-induced effects in OL-progenitors. pirinixic acid 13-20 peroxisome proliferator activated receptor alpha Mus musculus 24-79 18301758-7 2008 In addition, the majority of genes regulated by unsaturated fatty acids, especially docosahexaenoic acid, were also regulated by the specific PPARalpha agonist WY14643. pirinixic acid 160-167 peroxisome proliferator activated receptor alpha Mus musculus 142-151 18301758-9 2008 Interestingly, using Nuclear Receptor PamChip(R) Arrays, fatty acid- and WY14643-induced interactions between PPARalpha and coregulators were found to be highly similar, although several PPARalpha-coactivator interactions specific for WY14643 were identified. pirinixic acid 73-80 peroxisome proliferator activated receptor alpha Mus musculus 110-119 17963696-3 2007 These results were further confirmed by the use of PPARalpha knockout mice in which AhR induction by WY14643 was abrogated. pirinixic acid 101-108 peroxisome proliferator activated receptor alpha Mus musculus 51-60 17951219-5 2008 Furthermore, WY14643 increased PPARalpha gene expression and the expression of the cardiogenic transcription factors GATA-4, Nkx2.5, DTEF-1, and MEF 2C. pirinixic acid 13-20 peroxisome proliferator activated receptor alpha Mus musculus 31-40 17891158-6 2007 KEY RESULTS: PPARalpha agonists GW7647 and WY14643 reduced LPS-induced NO production in a dose-dependent manner as measured by the accumulation of nitrite into the culture medium. pirinixic acid 43-50 peroxisome proliferator activated receptor alpha Mus musculus 13-22 18288265-8 2007 In wild-type mice fed a high fat diet, the decrease in hepatic lipids following treatment with the PPARalpha agonist Wy14643 was paralleled by significant up-regulation of Pnpla2, Lipe, and Mgll, suggesting that induction of triglyceride hydrolysis may contribute to the anti-steatotic role of PPARalpha. pirinixic acid 117-124 peroxisome proliferator activated receptor alpha Mus musculus 294-303 17405874-6 2007 All these Wy-14643-induced responses were absent in PPARalpha(-/-) mice and are thus PPARalpha-mediated. pirinixic acid 10-18 peroxisome proliferator activated receptor alpha Mus musculus 52-61 17405874-6 2007 All these Wy-14643-induced responses were absent in PPARalpha(-/-) mice and are thus PPARalpha-mediated. pirinixic acid 10-18 peroxisome proliferator activated receptor alpha Mus musculus 85-94 17321000-4 2007 RESULTS: According to Affymetrix micro-array analysis, the expression of various inflammatory genes in liver was decreased by treatment of mice with the synthetic PPARalpha agonist Wy14643 in a PPARalpha-dependent manner. pirinixic acid 181-188 peroxisome proliferator activated receptor alpha Mus musculus 163-172 17321000-4 2007 RESULTS: According to Affymetrix micro-array analysis, the expression of various inflammatory genes in liver was decreased by treatment of mice with the synthetic PPARalpha agonist Wy14643 in a PPARalpha-dependent manner. pirinixic acid 181-188 peroxisome proliferator activated receptor alpha Mus musculus 194-203 17151188-4 2007 Oral administration of the PPARalpha agonist 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (pirinixic acid, WY-14643) to Tg-UGT1 mice led to induction of these proteins in either the liver, gastrointestinal tract, or kidney. pirinixic acid 45-99 peroxisome proliferator activated receptor alpha Mus musculus 27-36 17151188-4 2007 Oral administration of the PPARalpha agonist 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (pirinixic acid, WY-14643) to Tg-UGT1 mice led to induction of these proteins in either the liver, gastrointestinal tract, or kidney. pirinixic acid 101-115 peroxisome proliferator activated receptor alpha Mus musculus 27-36 17151188-4 2007 Oral administration of the PPARalpha agonist 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (pirinixic acid, WY-14643) to Tg-UGT1 mice led to induction of these proteins in either the liver, gastrointestinal tract, or kidney. pirinixic acid 117-125 peroxisome proliferator activated receptor alpha Mus musculus 27-36 17113579-9 2007 Wy-14,643 (30 microM) and fenofibrate (100 microM) inhibited the cysteinyl leukotriene production in bone marrow-derived mast cells from PPARalpha-null mice. pirinixic acid 0-9 peroxisome proliferator activated receptor alpha Mus musculus 137-146 17467307-8 2007 Moreover, cardiomyocyte differentiation of EBs could be efficiently stimulated by WY14643 treatment, the specific agonist of PPARalpha. pirinixic acid 82-89 peroxisome proliferator activated receptor alpha Mus musculus 125-134 18288265-8 2007 In wild-type mice fed a high fat diet, the decrease in hepatic lipids following treatment with the PPARalpha agonist Wy14643 was paralleled by significant up-regulation of Pnpla2, Lipe, and Mgll, suggesting that induction of triglyceride hydrolysis may contribute to the anti-steatotic role of PPARalpha. pirinixic acid 117-124 peroxisome proliferator activated receptor alpha Mus musculus 99-108 17084873-7 2006 In particular, diclofop-methyl induced as high levels of CYP4A mRNAs as WY-14643, a potent PPARalpha agonist. pirinixic acid 72-80 peroxisome proliferator activated receptor alpha Mus musculus 91-100 16777972-7 2006 Next, to evaluate whether brain PPARalpha could affect glucose homeostasis, we activated brain PPARalpha in wild-type mice by infusing WY14643 into the lateral ventricle and showed that whole-body glucose use was reduced. pirinixic acid 135-142 peroxisome proliferator activated receptor alpha Mus musculus 95-104 16807375-4 2006 Constitutive expression of ACMSD mRNA levels were governed by HNF4alpha and downregulated by activation of PPARalpha by the ligand Wy-14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid]), as revealed by studies with hepatic HNF4alpha-null mice and PPARalpha-null mice, respectively. pirinixic acid 131-140 peroxisome proliferator activated receptor alpha Mus musculus 107-116 16807375-4 2006 Constitutive expression of ACMSD mRNA levels were governed by HNF4alpha and downregulated by activation of PPARalpha by the ligand Wy-14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid]), as revealed by studies with hepatic HNF4alpha-null mice and PPARalpha-null mice, respectively. pirinixic acid 142-198 peroxisome proliferator activated receptor alpha Mus musculus 107-116 16807375-4 2006 Constitutive expression of ACMSD mRNA levels were governed by HNF4alpha and downregulated by activation of PPARalpha by the ligand Wy-14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid]), as revealed by studies with hepatic HNF4alpha-null mice and PPARalpha-null mice, respectively. pirinixic acid 142-198 peroxisome proliferator activated receptor alpha Mus musculus 262-271 16790840-3 2006 Studies with peroxisome proliferator-activated receptor alpha (PPARalpha)-deficient mice establish that PPARalpha was required for WY14643-mediated induction of fatty acid elongase-5 (Elovl-5), Elovl-6, and all three desaturases [Delta(5) desaturase (Delta(5)D), Delta(6)D, and Delta(9)D]. pirinixic acid 131-138 peroxisome proliferator activated receptor alpha Mus musculus 13-61 16790840-3 2006 Studies with peroxisome proliferator-activated receptor alpha (PPARalpha)-deficient mice establish that PPARalpha was required for WY14643-mediated induction of fatty acid elongase-5 (Elovl-5), Elovl-6, and all three desaturases [Delta(5) desaturase (Delta(5)D), Delta(6)D, and Delta(9)D]. pirinixic acid 131-138 peroxisome proliferator activated receptor alpha Mus musculus 63-72 16790840-3 2006 Studies with peroxisome proliferator-activated receptor alpha (PPARalpha)-deficient mice establish that PPARalpha was required for WY14643-mediated induction of fatty acid elongase-5 (Elovl-5), Elovl-6, and all three desaturases [Delta(5) desaturase (Delta(5)D), Delta(6)D, and Delta(9)D]. pirinixic acid 131-138 peroxisome proliferator activated receptor alpha Mus musculus 104-113 16764943-4 2006 Our studies demonstrated that the PPAR-alpha agonists fenofibrate, and WY 14643 inhibited NO production by LPS-stimulated astrocytes in a dose-dependent manner. pirinixic acid 71-79 peroxisome proliferator activated receptor alpha Mus musculus 34-44 16428347-9 2006 Culturing ARCs with oleate (0.1-0.4 mM) or the PPARalpha agonists WY-14643 (1 muM) and fenofibrate (10 muM) consistently induced acsl1 and cte1. pirinixic acid 66-74 peroxisome proliferator activated receptor alpha Mus musculus 47-56 15797250-8 2005 In confluent cultures of human hepatoma HepG2 cells that stably express a mouse peroxisome proliferator activated receptor-alpha (PPARalpha) mutant, CYP4X1 mRNA was undetectable in vehicle-treated cells but was readily detectable following addition of the PPARalpha agonist Wy14643. pirinixic acid 274-281 peroxisome proliferator activated receptor alpha Mus musculus 80-128 16086669-3 2005 Hepatic expression of G0S2 was up-regulated by fasting and by the PPARalpha agonist Wy14643 in a PPARalpha-dependent manner. pirinixic acid 84-91 peroxisome proliferator activated receptor alpha Mus musculus 66-75 16086669-3 2005 Hepatic expression of G0S2 was up-regulated by fasting and by the PPARalpha agonist Wy14643 in a PPARalpha-dependent manner. pirinixic acid 84-91 peroxisome proliferator activated receptor alpha Mus musculus 97-106 15465922-5 2005 The natural PPAR-alpha agonist oleoylethanolamide (OEA) and the synthetic PPAR-alpha agonists GW7647 and Wy-14643 mimic these effects in a PPAR-alpha-dependent manner. pirinixic acid 105-113 peroxisome proliferator activated receptor alpha Mus musculus 74-84 15465922-5 2005 The natural PPAR-alpha agonist oleoylethanolamide (OEA) and the synthetic PPAR-alpha agonists GW7647 and Wy-14643 mimic these effects in a PPAR-alpha-dependent manner. pirinixic acid 105-113 peroxisome proliferator activated receptor alpha Mus musculus 74-84 14960661-5 2004 Coadministration of T0901317 and the specific PPARalpha agonist [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (Wy14643)] in mice led to synergistic elevation of HDL cholesterol that was primarily associated with enlarged HDL particles enriched with apoE and apoAI. pirinixic acid 65-119 peroxisome proliferator activated receptor alpha Mus musculus 46-55 15123613-10 2004 The synthetic PPAR-alpha agonist Wy-14643 produced similar effects, which also were dependent on the presence of PPAR-alpha. pirinixic acid 33-41 peroxisome proliferator activated receptor alpha Mus musculus 14-24 15123613-10 2004 The synthetic PPAR-alpha agonist Wy-14643 produced similar effects, which also were dependent on the presence of PPAR-alpha. pirinixic acid 33-41 peroxisome proliferator activated receptor alpha Mus musculus 113-123 15232616-4 2004 Furthermore, expression of these genes was induced by the PPARalpha agonist Wy14643 in wild-type but not PPARalpha-null mice. pirinixic acid 76-83 peroxisome proliferator activated receptor alpha Mus musculus 58-67 15232616-8 2004 Finally, hepatic glucose production was decreased in PPARalpha-null mice simultaneously fasted and exposed to Wy14643, suggesting that the stimulatory effect of PPARalpha on gluconeogenic gene expression was translated at the functional level. pirinixic acid 110-117 peroxisome proliferator activated receptor alpha Mus musculus 53-62 15232616-8 2004 Finally, hepatic glucose production was decreased in PPARalpha-null mice simultaneously fasted and exposed to Wy14643, suggesting that the stimulatory effect of PPARalpha on gluconeogenic gene expression was translated at the functional level. pirinixic acid 110-117 peroxisome proliferator activated receptor alpha Mus musculus 161-170 14960661-5 2004 Coadministration of T0901317 and the specific PPARalpha agonist [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (Wy14643)] in mice led to synergistic elevation of HDL cholesterol that was primarily associated with enlarged HDL particles enriched with apoE and apoAI. pirinixic acid 121-128 peroxisome proliferator activated receptor alpha Mus musculus 46-55 11108658-3 2000 In an initiation-promotion study, SENCAR mice treated topically with the PPARalpha ligands conjugated linoleic acid and 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (Wy-14643) exhibited an approximately 30% lower skin tumor yield compared with mice treated with vehicle. pirinixic acid 120-174 peroxisome proliferator activated receptor alpha Mus musculus 73-82 14615282-6 2004 Consistent with these findings, C57BL/6 mice treated with the PPARalpha agonist, WY-14643, had significantly less liver injury than mice receiving vehicle. pirinixic acid 81-89 peroxisome proliferator activated receptor alpha Mus musculus 62-71 14615282-10 2004 Finally, treatment of cultured murine hepatocytes with WY-14643, a specific agonist of PPARalpha, protected cells against oxidant-induced injury. pirinixic acid 55-63 peroxisome proliferator activated receptor alpha Mus musculus 87-96 15030165-6 2004 The more potent and specific PPARalpha agonist WY 14643, 1 microM, also reduced palmitate-induced apoptosis but to a smaller extent than fenofibrate. pirinixic acid 47-55 peroxisome proliferator activated receptor alpha Mus musculus 29-38 12860474-3 2003 For that purpose, we used WY14643 [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio acetic acid] as a PPARalpha agonist, L-165041 and L-783483 as PPARbeta ligands, and 15-deoxy-Delta(12,14)-PGJ2 (15d-PGJ2), troglitazone, and ciglitazone for PPARgamma. pirinixic acid 26-33 peroxisome proliferator activated receptor alpha Mus musculus 97-106 12614196-7 2003 The up-regulated 24p3 mRNA expression by MK886 was enhanced a further 3.1-fold by WY14643, an activator of peroxisome-proliferator-activated receptor alpha, whereas ciglitazone, an activator of peroxisome-proliferator-activated receptor gamma attenuated the MK886-induced 24p3 expression by more than 50%. pirinixic acid 82-89 peroxisome proliferator activated receptor alpha Mus musculus 107-155 15122757-2 2004 We have previously shown that the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, Wy-14,643, prevented the development of MCD diet-induced steatohepatitis. pirinixic acid 104-113 peroxisome proliferator activated receptor alpha Mus musculus 34-82 15122757-2 2004 We have previously shown that the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, Wy-14,643, prevented the development of MCD diet-induced steatohepatitis. pirinixic acid 104-113 peroxisome proliferator activated receptor alpha Mus musculus 84-93 12759335-8 2003 Treatment of mice with the PPARalpha/gamma agonist WY14643 increases BCM protein expression in liver. pirinixic acid 51-58 peroxisome proliferator activated receptor alpha Mus musculus 27-36 11782473-4 2002 Addition of PPARalpha activators, WY14,643 or fenofibrate, to cultured hepatocytes up-regulated UCP2 mRNA by 5-10-fold. pirinixic acid 34-42 peroxisome proliferator activated receptor alpha Mus musculus 12-21 11532977-6 2001 Direct activation of PPARalpha using the synthetic PPARalpha ligand WY14643 decreased mRNA levels of these genes, suggesting that PPARalpha is directly implicated in the regulation of their expression. pirinixic acid 68-75 peroxisome proliferator activated receptor alpha Mus musculus 21-30 11532977-6 2001 Direct activation of PPARalpha using the synthetic PPARalpha ligand WY14643 decreased mRNA levels of these genes, suggesting that PPARalpha is directly implicated in the regulation of their expression. pirinixic acid 68-75 peroxisome proliferator activated receptor alpha Mus musculus 51-60 11532977-6 2001 Direct activation of PPARalpha using the synthetic PPARalpha ligand WY14643 decreased mRNA levels of these genes, suggesting that PPARalpha is directly implicated in the regulation of their expression. pirinixic acid 68-75 peroxisome proliferator activated receptor alpha Mus musculus 51-60 11505017-10 2001 Treatment of the mice with the PPARalpha agonist WY14643 slightly decreased the level of ALDH2 protein in both wild-type and PPARalpha-null mice, suggesting that the effect of WY14643 was not mediated by the receptor. pirinixic acid 49-56 peroxisome proliferator activated receptor alpha Mus musculus 31-40 11505017-10 2001 Treatment of the mice with the PPARalpha agonist WY14643 slightly decreased the level of ALDH2 protein in both wild-type and PPARalpha-null mice, suggesting that the effect of WY14643 was not mediated by the receptor. pirinixic acid 49-56 peroxisome proliferator activated receptor alpha Mus musculus 125-134 11505017-10 2001 Treatment of the mice with the PPARalpha agonist WY14643 slightly decreased the level of ALDH2 protein in both wild-type and PPARalpha-null mice, suggesting that the effect of WY14643 was not mediated by the receptor. pirinixic acid 176-183 peroxisome proliferator activated receptor alpha Mus musculus 31-40 11108658-3 2000 In an initiation-promotion study, SENCAR mice treated topically with the PPARalpha ligands conjugated linoleic acid and 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (Wy-14643) exhibited an approximately 30% lower skin tumor yield compared with mice treated with vehicle. pirinixic acid 176-184 peroxisome proliferator activated receptor alpha Mus musculus 73-82 10581215-6 1999 A decreased sensitivity of human PPARalpha compared to mouse PPARalpha to trans-activation was observed with some (Wy-14, 643, PFOA), but not other, peroxisome proliferators (TCE metabolites, trichloroacetate and dichloroacetate; and DEHP metabolites, mono[2-ethylhexyl]phthalate and 2-ethylhexanoic acid). pirinixic acid 115-125 peroxisome proliferator activated receptor alpha Mus musculus 61-70 7565638-5 1995 The mPPAR alpha-G mutant receptor displays a higher EC50 for pirinixic acid and for 5,8,11,14-eicosatetraynoic acid than the wild-type PPAR alpha. pirinixic acid 61-75 peroxisome proliferator activated receptor alpha Mus musculus 4-15 7565638-5 1995 The mPPAR alpha-G mutant receptor displays a higher EC50 for pirinixic acid and for 5,8,11,14-eicosatetraynoic acid than the wild-type PPAR alpha. pirinixic acid 61-75 peroxisome proliferator activated receptor alpha Mus musculus 5-15 34265279-0 2021 PPARalpha agonist WY-14,643 induces adipose atrophy and fails to blunt chronic ethanol-induced hepatic fat accumulation in mice lacking adipose FGFR1. pirinixic acid 18-27 peroxisome proliferator activated receptor alpha Mus musculus 0-9 23008696-2 2012 The PPARalpha agonists GW7647, WY14643, and gemfibrozil acutely relaxed aortas held under isometric tension and dilated pressurized MCAs with the following order of potency: GW7647>>WY14643>gemfibrozil. pirinixic acid 31-38 peroxisome proliferator activated receptor alpha Mus musculus 4-13 23008696-2 2012 The PPARalpha agonists GW7647, WY14643, and gemfibrozil acutely relaxed aortas held under isometric tension and dilated pressurized MCAs with the following order of potency: GW7647>>WY14643>gemfibrozil. pirinixic acid 188-195 peroxisome proliferator activated receptor alpha Mus musculus 4-13 23008696-6 2012 In aortas, GW7647 and WY14643 elevated cGMP levels by stimulating soluble guanylyl cyclase (sGC), and inhibition of sGC with ODQ blunted relaxations to PPARalpha agonists. pirinixic acid 22-29 peroxisome proliferator activated receptor alpha Mus musculus 152-161 34387904-4 2022 PPARalpha activation by the specific agonist WY-14643 significantly induced hepatomegaly and accelerated liver regeneration after 70% partial hepatectomy (PHx) in wild-type mice and Pparafl/fl mice, while these effects were abolished in hepatocyte-specific Pparalpha-deficient (PparaDeltaHep ) mice. pirinixic acid 45-53 peroxisome proliferator activated receptor alpha Mus musculus 0-9 22966226-4 2012 Carotid artery injury was performed in the PPARalpha knockout and wild type (WT) mice, treated and untreated with Wy14643, a PPARalpha activator. pirinixic acid 114-121 peroxisome proliferator activated receptor alpha Mus musculus 125-134 34390780-4 2021 Mouse studies were conducted to determine the effect of PPARalpha reactivation by Wy14,643 on alcoholic hepatotoxicity and how catalase is involved in mediating such effects. pirinixic acid 82-90 peroxisome proliferator activated receptor alpha Mus musculus 56-65 34390780-7 2021 PPARalpha reactivation by Wy14,643 effectively reversed alcohol-induced liver damage in mice. pirinixic acid 26-34 peroxisome proliferator activated receptor alpha Mus musculus 0-9 32506644-4 2020 Mouse primary hepatocytes were treated with the BCAA or a Pparalpha activator WY-14643 to systematically examine direct hepatic effects and their mechanisms. pirinixic acid 78-86 peroxisome proliferator activated receptor alpha Mus musculus 58-67 35007830-10 2022 In conclusion, PPAR alpha pathway participates in PM-induced lipid metabolism disorder, PPAR alpha agonist WY14,643 treatment exerted protective effects on PM-induced dyslipidemia, liver steatosis and whitening of BAT, but not on increased adipocyte size of WAT. pirinixic acid 107-115 peroxisome proliferator activated receptor alpha Mus musculus 15-25 35007830-10 2022 In conclusion, PPAR alpha pathway participates in PM-induced lipid metabolism disorder, PPAR alpha agonist WY14,643 treatment exerted protective effects on PM-induced dyslipidemia, liver steatosis and whitening of BAT, but not on increased adipocyte size of WAT. pirinixic acid 107-115 peroxisome proliferator activated receptor alpha Mus musculus 88-98 35526488-0 2022 PPARalpha agonist WY-14,643 induces the PLA2/COX-2/ACOX1 pathway to enhance peroxisomal lipid metabolism and ameliorate alcoholic fatty liver in mice. pirinixic acid 18-27 peroxisome proliferator activated receptor alpha Mus musculus 0-9 33835704-7 2021 The observed vasodilatory impairment of mesenteric arteries was ameliorated by PPARalpha agonist WY-14643. pirinixic acid 97-105 peroxisome proliferator activated receptor alpha Mus musculus 79-88 33754023-14 2021 Activating PPARalpha with WY14643 in primarily cultured Rap1-/- cardiomyocytes restored maximal oxygen consumption rates. pirinixic acid 26-33 peroxisome proliferator activated receptor alpha Mus musculus 11-20 32826849-6 2020 Moreover, PPARalpha inhibition by siRNA promoted cell injury in the mild-ER stress and PPARalpha activation by WY-14643 reduced cell apoptosis in the serious ER stress. pirinixic acid 111-119 peroxisome proliferator activated receptor alpha Mus musculus 10-19 32826849-6 2020 Moreover, PPARalpha inhibition by siRNA promoted cell injury in the mild-ER stress and PPARalpha activation by WY-14643 reduced cell apoptosis in the serious ER stress. pirinixic acid 111-119 peroxisome proliferator activated receptor alpha Mus musculus 87-96 32534105-11 2020 Furthermore, Wy14643, a classical PPARalpha agonist, induced mRNA expression of Hoxb7 and c5 in wild-type but not PPARalpha-null mouse livers. pirinixic acid 13-20 peroxisome proliferator activated receptor alpha Mus musculus 34-43 32791799-3 2020 PPARalpha was activated by Wy-14643. pirinixic acid 27-35 peroxisome proliferator activated receptor alpha Mus musculus 0-9 30957417-9 2019 Furthermore, we confirmed that PPARalpha and PPARgamma activation by WY14643 and pioglitazone, respectively, alleviated oleate-induced accumulation of total cholesterol, esterified cholesterol and neutral lipids by accelerating ABC transporter A1/G1-mediated cholesterol efflux. pirinixic acid 69-76 peroxisome proliferator activated receptor alpha Mus musculus 31-40 30729704-0 2019 Chondroprotection of PPARalpha activation by WY14643 via autophagy involving Akt and ERK in LPS-treated mouse chondrocytes and osteoarthritis model. pirinixic acid 45-52 peroxisome proliferator activated receptor alpha Mus musculus 21-30 30729704-8 2019 The results indicated that PPARalpha activation by WY14643 promoted proteoglycan synthesis by autophagy enhancement in OA chondrocytes in vivo and in vitro concomitant with the elevation of Akt and ERK phosphorylation. pirinixic acid 51-58 peroxisome proliferator activated receptor alpha Mus musculus 27-36 30729704-9 2019 Therefore, autophagy could contribute to the chondroprotection of PPARalpha activation by WY14643, with the implication that PPARalpha activation by WY14643 may be a potential approach for OA therapy. pirinixic acid 90-97 peroxisome proliferator activated receptor alpha Mus musculus 66-75 30729704-9 2019 Therefore, autophagy could contribute to the chondroprotection of PPARalpha activation by WY14643, with the implication that PPARalpha activation by WY14643 may be a potential approach for OA therapy. pirinixic acid 149-156 peroxisome proliferator activated receptor alpha Mus musculus 125-134 30729704-5 2019 In this study, we investigated the effect of PPARalpha activation by its agonist, WY14643, on the protein expression level of Aggrecan and ADAMTS5, and the protein expression level of autophagy biomarkers, including LC3B and P62, using Western blotting analysis in isolated mouse chondrocytes pre-treated with lipopolysaccharides (LPS, mimicking OA chondrocytes) with or without the autophagy inhibitor chloroquine diphosphate salt. pirinixic acid 82-89 peroxisome proliferator activated receptor alpha Mus musculus 45-54 28711683-0 2017 Anti-obesogenic effects of WY14643 (PPAR-alpha agonist): Hepatic mitochondrial enhancement and suppressed lipogenic pathway in diet-induced obese mice. pirinixic acid 27-34 peroxisome proliferator activated receptor alpha Mus musculus 36-46 29659121-7 2018 Cardioprotection in DM mediated by exendin-4 was abolished by combination therapy with the PPARalpha agonist wy-14643 but mimicked by PPARalpha gene deficiency. pirinixic acid 109-117 peroxisome proliferator activated receptor alpha Mus musculus 91-100 29722018-3 2018 We have previously reported that both WY14643 and fenofibrate, two pharmacological agonists of PPARalpha, have antidepressant-like effects in mice, implying that PPARalpha is a potential antidepressant target. pirinixic acid 38-45 peroxisome proliferator activated receptor alpha Mus musculus 95-104 29722018-3 2018 We have previously reported that both WY14643 and fenofibrate, two pharmacological agonists of PPARalpha, have antidepressant-like effects in mice, implying that PPARalpha is a potential antidepressant target. pirinixic acid 38-45 peroxisome proliferator activated receptor alpha Mus musculus 162-171 30504232-7 2019 As expected, the corresponding lncRNAs were significantly elevated in AML12 cells treated with palmitic acid or the PPARalpha agonist, WY14643. pirinixic acid 135-142 peroxisome proliferator activated receptor alpha Mus musculus 116-125 29141109-0 2018 Hepatic peroxisome proliferator-activated receptor alpha mediates the major metabolic effects of Wy-14643. pirinixic acid 97-105 peroxisome proliferator activated receptor alpha Mus musculus 8-56 29141109-4 2018 METHODS: A hepatocyte-specific Ppara knockout mouse line was used to explore the impact of hepatic PPARalpha activity on the systemic response to treatment with the potent PPARalpha agonist Wy-14643. pirinixic acid 190-198 peroxisome proliferator activated receptor alpha Mus musculus 31-36 29141109-4 2018 METHODS: A hepatocyte-specific Ppara knockout mouse line was used to explore the impact of hepatic PPARalpha activity on the systemic response to treatment with the potent PPARalpha agonist Wy-14643. pirinixic acid 190-198 peroxisome proliferator activated receptor alpha Mus musculus 172-181 29141109-6 2018 Hepatic Ppara disruption abolished the triglyceride lowering effects of Wy-14643, prevented agonist-induced hypophagia, and ablated PPARalpha target gene response in the liver. pirinixic acid 72-80 peroxisome proliferator activated receptor alpha Mus musculus 8-13 29141109-7 2018 CONCLUSIONS: These findings indicate that Wy-14643 treatment mainly activates hepatic PPARalpha, and the hypolipidemic and hypophagic effects of Wy-14643 are dependent on PPARalpha activation within hepatocytes. pirinixic acid 42-50 peroxisome proliferator activated receptor alpha Mus musculus 86-95 29141109-7 2018 CONCLUSIONS: These findings indicate that Wy-14643 treatment mainly activates hepatic PPARalpha, and the hypolipidemic and hypophagic effects of Wy-14643 are dependent on PPARalpha activation within hepatocytes. pirinixic acid 145-153 peroxisome proliferator activated receptor alpha Mus musculus 171-180 28600667-5 2017 METHODS: In a murine model induced by D-galactosamine (D-GalN, 700 mg/kg) and LPS (10 mug/kg), Wy-14643 (6 mg/kg) was administered to activate PPARalpha. pirinixic acid 95-103 peroxisome proliferator activated receptor alpha Mus musculus 143-152 28007964-4 2017 Pretreating both HepG2 cells and primary mouse hepatocytes with the PPAR-alpha agonist, pirinixic acid (Wy 14643), increased the production of alpha-chlorodicarboxylic acids (alpha-ClDCAs) in cells treated with exogenous alpha-ClFA. pirinixic acid 88-102 peroxisome proliferator activated receptor alpha Mus musculus 68-78 28607105-8 2017 The effects of Acot1 knockdown on PPARalpha activity, oxidative stress, and inflammation were rescued by supplementation with Wy-14643, a synthetic PPARalpha ligand. pirinixic acid 126-134 peroxisome proliferator activated receptor alpha Mus musculus 34-43 28607105-8 2017 The effects of Acot1 knockdown on PPARalpha activity, oxidative stress, and inflammation were rescued by supplementation with Wy-14643, a synthetic PPARalpha ligand. pirinixic acid 126-134 peroxisome proliferator activated receptor alpha Mus musculus 148-157 28007964-4 2017 Pretreating both HepG2 cells and primary mouse hepatocytes with the PPAR-alpha agonist, pirinixic acid (Wy 14643), increased the production of alpha-chlorodicarboxylic acids (alpha-ClDCAs) in cells treated with exogenous alpha-ClFA. pirinixic acid 104-112 peroxisome proliferator activated receptor alpha Mus musculus 68-78 28017641-0 2017 WY-14643, a selective agonist of peroxisome proliferator-activated receptor-alpha, ameliorates lipopolysaccharide-induced depressive-like behaviors by preventing neuroinflammation and oxido-nitrosative stress in mice. pirinixic acid 0-8 peroxisome proliferator activated receptor alpha Mus musculus 33-81 28017641-4 2017 WY-14643, an agonist of peroxisome proliferator-activated receptor-alpha (PPAR-alpha), has been reported to inhibit neuroinflammation and oxidative stress, and one of our previous studies have showed that WY-14643 possesses antidepressive activities. pirinixic acid 0-8 peroxisome proliferator activated receptor alpha Mus musculus 24-72 28017641-4 2017 WY-14643, an agonist of peroxisome proliferator-activated receptor-alpha (PPAR-alpha), has been reported to inhibit neuroinflammation and oxidative stress, and one of our previous studies have showed that WY-14643 possesses antidepressive activities. pirinixic acid 0-8 peroxisome proliferator activated receptor alpha Mus musculus 74-84 28017641-4 2017 WY-14643, an agonist of peroxisome proliferator-activated receptor-alpha (PPAR-alpha), has been reported to inhibit neuroinflammation and oxidative stress, and one of our previous studies have showed that WY-14643 possesses antidepressive activities. pirinixic acid 205-213 peroxisome proliferator activated receptor alpha Mus musculus 24-72 28017641-4 2017 WY-14643, an agonist of peroxisome proliferator-activated receptor-alpha (PPAR-alpha), has been reported to inhibit neuroinflammation and oxidative stress, and one of our previous studies have showed that WY-14643 possesses antidepressive activities. pirinixic acid 205-213 peroxisome proliferator activated receptor alpha Mus musculus 74-84 27422264-1 2016 WY14643 is a selective agonist of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) with neuroprotective and neurotrophic effects. pirinixic acid 0-7 peroxisome proliferator activated receptor alpha Mus musculus 34-82 27422264-1 2016 WY14643 is a selective agonist of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) with neuroprotective and neurotrophic effects. pirinixic acid 0-7 peroxisome proliferator activated receptor alpha Mus musculus 84-94 27422264-6 2016 The usage of both PPAR-alpha inhibitor GW6471 and BDNF system inhibitor K252a fully prevented the memory-enhancing effects of WY14643. pirinixic acid 126-133 peroxisome proliferator activated receptor alpha Mus musculus 18-28 27422264-7 2016 Therefore, these findings suggest that WY14643 could improve the scopolamine-induced memory impairments, and these effects are mediated by the activation of PPAR-alpha and BDNF system, thereby exhibiting a cognition-enhancing potential. pirinixic acid 39-46 peroxisome proliferator activated receptor alpha Mus musculus 157-167 25896250-10 2015 Clofibrate, Ciprofibrate, and WY-14643: three agents used for treatment of metabolic disorders, were found to promote PPAR-alpha expression while decreasing miR-17-5p levels and inhibiting steatosis. pirinixic acid 30-38 peroxisome proliferator activated receptor alpha Mus musculus 118-128 26125906-4 2015 This study investigated the effects of the PPARalpha-agonist WY14643 combined with t-RA, on the "browning" of white adipocytes in mice mediated by UCP1, and the molecular mechanisms involved in this process. pirinixic acid 61-68 peroxisome proliferator activated receptor alpha Mus musculus 43-52 27482818-5 2016 In a murine model of D-galactosamine (D-GalN)- and lipopolysaccharide (LPS)-induced ALF, Wy-14643 was administered to activate PPARalpha, and 4-phenylbutyric acid (4-PBA) was administered to attenuate ER stress. pirinixic acid 89-97 peroxisome proliferator activated receptor alpha Mus musculus 127-136 25913736-3 2015 To assess the effects of peroxisomal proliferation on FA oxidation independent of n-3 PUFA intake, mice were treated with the PPAR-alpha agonist WY-14643. pirinixic acid 145-153 peroxisome proliferator activated receptor alpha Mus musculus 126-136 25511408-5 2014 WY14643 (6 mg/kg), the selective agonist of PPAR alpha, was administered via tail vein two hours prior to D-GalN/LPS exposure. pirinixic acid 0-7 peroxisome proliferator activated receptor alpha Mus musculus 44-54 25388293-2 2015 OBJECTIVES: WY14643 is a selective agonist of peroxisome proliferator-activated receptor-alpha with neuroprotective and neurotrophic effects. pirinixic acid 12-19 peroxisome proliferator activated receptor alpha Mus musculus 46-94 25703193-7 2015 Ligand activation of PPARalpha in Cyp1b1-ko mice by WY-14643 was, nevertheless, effective. pirinixic acid 52-60 peroxisome proliferator activated receptor alpha Mus musculus 21-30 25695641-5 2015 Wy14643, a selective PPARalpha agonist, significantly induced Igfbp-2 gene expression in primary cultured hepatocytes. pirinixic acid 0-7 peroxisome proliferator activated receptor alpha Mus musculus 21-30 25695641-8 2015 To explore the role of PPARalpha in IGF-1 signalling, we treated primary cultured hepatocytes with Wy14643 and observed a decrease in the number of IGF-1 receptors (IGF-1Rs) and in Akt phosphorylation. pirinixic acid 99-106 peroxisome proliferator activated receptor alpha Mus musculus 23-32 25695641-10 2015 These results suggest that PPARalpha controls IGF-1 signalling through the up-regulation of hepatic Igfbp-2 transcription during fasting and Wy14643 treatment. pirinixic acid 141-148 peroxisome proliferator activated receptor alpha Mus musculus 27-36 25511156-4 2014 The aim was to obtain a comprehensive view of common and model-specific PPARalpha-dependent genes and biological processes to understand the impact of cross-talk between parenchymal and non-parenchymal fractions as well as the effect of inter-organ interactions on the hepatic PPARalpha transcriptome.To this end we analyzed microarray data of experiments performed in mouse primary hepatocytes treated with the PPARalpha agonist Wy14643 for 6 or 24 h (in vitro), mouse precision cut liver slices treated with Wy14643 for 24 h (ex vivo), and livers of wild type and Ppara knockout mice treated with Wy14643 for 6 h or 5 days (in vivo). pirinixic acid 430-437 peroxisome proliferator activated receptor alpha Mus musculus 72-81 25511156-4 2014 The aim was to obtain a comprehensive view of common and model-specific PPARalpha-dependent genes and biological processes to understand the impact of cross-talk between parenchymal and non-parenchymal fractions as well as the effect of inter-organ interactions on the hepatic PPARalpha transcriptome.To this end we analyzed microarray data of experiments performed in mouse primary hepatocytes treated with the PPARalpha agonist Wy14643 for 6 or 24 h (in vitro), mouse precision cut liver slices treated with Wy14643 for 24 h (ex vivo), and livers of wild type and Ppara knockout mice treated with Wy14643 for 6 h or 5 days (in vivo). pirinixic acid 510-517 peroxisome proliferator activated receptor alpha Mus musculus 72-81 25511156-4 2014 The aim was to obtain a comprehensive view of common and model-specific PPARalpha-dependent genes and biological processes to understand the impact of cross-talk between parenchymal and non-parenchymal fractions as well as the effect of inter-organ interactions on the hepatic PPARalpha transcriptome.To this end we analyzed microarray data of experiments performed in mouse primary hepatocytes treated with the PPARalpha agonist Wy14643 for 6 or 24 h (in vitro), mouse precision cut liver slices treated with Wy14643 for 24 h (ex vivo), and livers of wild type and Ppara knockout mice treated with Wy14643 for 6 h or 5 days (in vivo). pirinixic acid 510-517 peroxisome proliferator activated receptor alpha Mus musculus 72-81 24876382-3 2014 Microarray analysis revealed that Hilpda is one of the most highly induced genes by the PPARalpha agonist Wy14643 in mouse precision cut liver slices. pirinixic acid 106-113 peroxisome proliferator activated receptor alpha Mus musculus 88-97